Cargando…

Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development

Licensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus (HPV) types have been a great success in reducing anogenital cancers, although they are limited in their cross-protection against HPV types not covered by the vaccine. Further, their utility in protection against cuta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmels, Melinda, Mariz, Filipe C., Braspenning-Wesch, Ilona, Stephan, Sonja, Huber, Bettina, Schmidt, Gabriele, Cao, Rui, Müller, Martin, Kirnbauer, Reinhard, Rösl, Frank, Hasche, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574214/ https://www.ncbi.nlm.nih.gov/pubmed/36263027 http://dx.doi.org/10.3389/fimmu.2022.1010790

Ejemplares similares

Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation
por: Hasche, Daniel, et al.
Publicado: (2022)

The interplay of UV and cutaneous papillomavirus infection in skin cancer development
por: Hasche, Daniel, et al.
Publicado: (2017)

Cutaneous HPV23 E6 Prevents p53 Phosphorylation through Interaction with HIPK2
por: Muschik, Dorothea, et al.
Publicado: (2011)

Expression of different L1 isoforms of Mastomys natalensis papillomavirus as mechanism to circumvent adaptive immunity
por: Fu, Yingying, et al.
Publicado: (2020)

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)
por: Huber, Bettina, et al.
Publicado: (2017)

Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?
por: Hasche, Daniel, et al.
Publicado: (2018)

Protective Vaccination against Papillomavirus-Induced Skin Tumors under Immunocompetent and Immunosuppressive Conditions: A Preclinical Study Using a Natural Outbred Animal Model
por: Vinzón, Sabrina E., et al.
Publicado: (2014)

Identification and Elimination of the Clinically Relevant Multi-Resistant Environmental Bacteria Ralstonia insidiosa in Primary Cell Culture
por: Nurjadi, Dennis, et al.
Publicado: (2020)

Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses
por: Schellenbacher, Christina, et al.
Publicado: (2013)

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates
por: Huber, Bettina, et al.
Publicado: (2021)

Mastomys Species as Model Systems for Infectious Diseases
por: Hasche, Daniel, et al.
Publicado: (2019)

A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus Types
por: Huber, Bettina, et al.
Publicado: (2015)

Establishment of an Immortalized Skin Keratinocyte Cell Line Derived from the Animal Model Mastomys coucha
por: Hasche, Daniel, et al.
Publicado: (2016)

A broadly protective vaccine against cutaneous human papillomaviruses
por: Mariz, Filipe Colaco, et al.
Publicado: (2022)

Papillomavirus-like Particles in Equine Medicine
por: Hainisch, Edmund K., et al.
Publicado: (2023)

Characterization of Novel Cutaneous Human Papillomavirus Genotypes HPV-150 and HPV-151
por: Kovanda, Anja, et al.
Publicado: (2011)

Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence
por: Namujju, Proscovia B, et al.
Publicado: (2011)

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach
por: Jindra, Christoph, et al.
Publicado: (2015)

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach
por: Jindra, Christoph, et al.
Publicado: (2015)

p53 Is Regulated in a Biphasic Manner in Hypoxic Human Papillomavirus Type 16 (HPV16)-Positive Cervical Cancer Cells
por: Zhuang, Linhan, et al.
Publicado: (2020)

Characterization of a Novel Cutaneous Human Papillomavirus Genotype HPV-125
por: Kovanda, Anja, et al.
Publicado: (2011)

Prevention and Treatment of HPV-Induced Skin Tumors
por: Hasche, Daniel, et al.
Publicado: (2023)

Natural History of Cutaneous Human Papillomavirus (HPV) Infection in Men: The HIM Study
por: Hampras, Shalaka S., et al.
Publicado: (2014)

Combined Transcriptome and Proteome Analysis of Immortalized Human Keratinocytes Expressing Human Papillomavirus 16 (HPV16) Oncogenes Reveals Novel Key Factors and Networks in HPV-Induced Carcinogenesis
por: Yang, Ruwen, et al.
Publicado: (2019)

Folate Repletion after Deficiency Induces Irreversible Genomic and Transcriptional Changes in Human Papillomavirus Type 16 (HPV16)-Immortalized Human Keratinocytes
por: Savini, Claudia, et al.
Publicado: (2019)

Impact of Inhibitors and L2 Antibodies upon the Infectivity of Diverse Alpha and Beta Human Papillomavirus Types
por: Kwak, Kihyuck, et al.
Publicado: (2014)

Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany
por: Loenenbach, Anna, et al.
Publicado: (2022)

Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids
por: Handisurya, A, et al.
Publicado: (2016)

High genital prevalence of cutaneous human papillomavirus DNA on male genital skin: the HPV Infection in Men Study
por: Sichero, Laura, et al.
Publicado: (2014)

IS THERE CORRELATION BETWEEN HUMAN PAPILLOMAVIRUS (HPV) AND ESOPHAGEAL EPIDERMOID CARCINOMA?
por: WOELLNER, Luiz Filipe Alkamin, et al.
Publicado: (2021)

Human papillomavirus spectrum of HPV-infected women in Nigeria: an analysis by next-generation sequencing and type-specific PCR
por: Dom-Chima, Ngozi, et al.
Publicado: (2023)

Human Papillomavirus 42 Drives Digital Papillary Adenocarcinoma and Elicits a Germ Cell–like Program Conserved in HPV-Positive Cancers
por: Leiendecker, Lukas, et al.
Publicado: (2023)

Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array
por: Nowak, Rebecca G., et al.
Publicado: (2017)

A pharmacist’s guide to human papillomavirus (HPV)
por: Cable, Cheryl E., et al.
Publicado: (2022)

Recent Developments in Human Papillomavirus (HPV) Vaccinology
por: Williamson, Anna-Lise
Publicado: (2023)

Interaction of HPV16 and Cutaneous HPV in Head and Neck Cancer
por: Al-Soneidar, Walid A., et al.
Publicado: (2022)

Genital and cutaneous human papillomavirus (HPV) types in relation to conjunctival squamous cell neoplasia: A case-control study in Uganda
por: de Koning, Maurits NC, et al.
Publicado: (2008)

Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2
por: Mariz, Filipe Colaco, et al.
Publicado: (2023)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation Human Papillomavirus (HPV) vaccines
por: Prabhu, Malavika, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1rdp8318j8bhrmj228fqabuqh7